Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate
- 281 Downloads
Numerous studies have recently shown that vitamin K2 (VK2) has antitumor effects in a variety of tumor cells, but there are few reports demonstrating antitumor effects of VK2 in vivo. The antitumor effects of VK2 in nanoemulsions are currently not known. Therefore, we sought to characterize the antitumor potential of VK2 nanoemulsions in S180 tumor cells in the present study. Furthermore, a ligand conjugate sialic acid–cholesterol, with enhanced affinity towards the membrane receptors overexpressed in tumors, was anchored on the surface of the nanoemulsions to increase VK2 distribution to the tumor tissue. VK2 was encapsulated in oil-in-water nanoemulsions, and the physical and chemical stability of the nanoemulsions were characterized during storage at 25 °C. At 25 °C, all nanoemulsions remained physically and chemically stable with little change in particle size. An in vivo study using syngeneic mice with subcutaneously established S180 tumors demonstrated that intravenous or intragastric administration of VK2 nanoemulsions significantly suppressed the tumor growth. The VK2 nanoemulsions modified with sialic acid–cholesterol conjugate showed higher tumor growth suppression than the VK2 nanoemulsions, while neither of them exhibited signs of drug toxicity. In summary, VK2 exerted effective antitumor effects in vivo, and VK2 nanoemulsions modified with sialic acid–cholesterol conjugate enhanced the antitumor activity, suggesting that these VK2 may be promising agents for the prevention or treatment of tumor in patients.
KeywordsVitamin K2 (menaquinone-7) Nanoemulsions Sialic acid–cholesterol Antitumor effects
This study was supported by the National Natural Science Foundation of China (81373334).
Compliance with ethical standards
Animal studies were performed in accordance with the Guidelines for Animal Experimentation of Shenyang Pharmaceutical University and approved by the Animal Ethics Committee of the institution.
- 7.O’Neil M. The Merck index. Merck & Co; 1989.Google Scholar
- 10.Villa JK, Diaz MA, Pizziolo VR, Martino HS. Effect of vitamin K in bone metabolism and vascular calcification: a review of mechanisms of action and evidences. Crit Rev Food Sci Nutr. 2016. https://doi.org/10.1080/10408398.2016.1211616
- 15.Azuma KIS. Aging mechanisms. Vitamin K benefits in aging and cancer. Japan: Springer; 2015.Google Scholar
- 19.Yokoyama T, Miyazawa K, Yoshida T, Ohyashiki K. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines. Int J Oncol 2005;26(1):33–40.Google Scholar
- 25.Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev J Clin Ther. 2003;8(3):303.Google Scholar
- 30.Samykutty A, Shetty AV, Dakshinamoorthy G, Kalyanasundaram R, Zheng G, Chen A, et al. Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med eCAM. 2013;2013(6):287358.PubMedGoogle Scholar
- 31.Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol. 2005;42(5):687–93.CrossRefPubMedGoogle Scholar
- 43.Nakamura H, Fang J, Maeda H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv. 2014;12(4):1–12.Google Scholar
- 44.Whiteside TL, editor. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Seminars in cancer biology. Elsevier; 2006.Google Scholar
- 46.D DW. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res. 1972;32(2):374–9.Google Scholar
- 49.Nath D, Hartnell A, Happerfield L, Miles DW, Burchell J, Taylorpapadimitriou J, et al. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology. 1999;98(2):213–9.CrossRefPubMedPubMedCentralGoogle Scholar